Ajanta Pharmaceuticals Ltd.
NSE: AJANTPHARMAjanta Pharmaceuticals Ltd.: A 30-second snapshot
Ajanta Pharma (NSE: AJANTPHARM) trades at Rs 3,177 as of the analysis date, up 29.4% over 12 months and 9.3% over the past three months, with the stock sitting above both its 50-DMA (Rs 2,908) and 200-DMA (Rs 2,698) and just 3.4% below its 52-week high. The company reported double-digit revenue and profit growth in FY2026 and guided for high-teen revenue growth with a 27% EBITDA margin for FY2027. A rising debt-to-equity ratio of 5.747 and a US FDA Form 483 with five observations at its Paithan plant are the two primary areas requiring monitoring.
P/E
37.6
Forward P/E
27.9
ROE
+25.4%
Debt / Equity
5.75
Profit Margin
+19.4%
Div. Yield
+1.8%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
73/100
News
6 headlines · 2 positive · 2 negative
AJANTPHARM: Double-digit revenue and profit growth achieved, with high teens growth and 27% EBITDA margin guided - TradingView
TradingView
AJANTPHARM: Strong FY 2026 growth with high-teen revenue and 27% EBITDA margin guidance for FY 2027 - TradingView
TradingView
Ajanta Pharma Receives US FDA Form 483 With Five Observations at Paithan Plant - TipRanks
TipRanks
Ajanta Pharma Promoter Aayush Agrawal Creates and Releases Pledge on 2,86,213 Shares Under SEBI (SAST) Regulations, 2011 - scanx.trade
scanx.trade
We Think That There Are Some Issues For Ajanta Pharma (NSE:AJANTPHARM) Beyond Its Promising Earnings - simplywall.st
simplywall.st
Recent context
- ·FY2026 results showed double-digit revenue and profit growth, with management guiding for high-teen revenue growth and a 27% EBITDA margin in FY2027; the forward PE of 27.9 versus the trailing 37.6 reflects the market pricing in this guidance delivery.
- ·US FDA issued a Form 483 with five observations at the Paithan manufacturing facility in April 2026; no public resolution timeline has been disclosed, and the event represents an open regulatory risk for US-market access.
- ·A SimplyWallSt analysis published May 13 2026 flagged concerns about earnings quality beyond headline growth, offering a cautionary counterpoint to the constructive FY2026 results narrative.
Strengths
- +ROE of 25.4% is the highest among the six pharma peers with available data — Cipla stands at 11.74% and Dr. Reddys at 11.84% — indicating materially superior return on capital deployed.
- +Quality score of 65 ranks first among six sector peers (next-highest: MAXHEALTH at 54, SUNPHARMA at 50), with a fundamental consistency score of 77 and ROE above 15% in 4 of the last 5 years.
- +Revenue has compounded at 21.5% over five years and earnings at 18.6%, with FCF positive in 4 of 5 available years, demonstrating a track record of translating top-line growth into cash generation.
- +Trailing PE of 37.6 ranks third among peers (APOLLOHOSP at 64.5, MAXHEALTH at 72.5, SUNPHARMA at 41.3 are all higher), while a forward PE of 27.9 reflects the growth expectations embedded in FY2027 management guidance.
Weaknesses
- −D/E of 5.747 on a rising trend is the primary financial-leverage concern; while pharma companies carry debt for capex, the trajectory is upward and the two peers with available data (Cipla, Dr. Reddys) operate at substantially lower leverage, making this an outlier within the sector sample.
- −US FDA Form 483 with five observations at the Paithan plant (April 2026) is a regulatory event that can escalate to a Warning Letter if not adequately resolved, restricting US export approvals — a material revenue channel for mid-cap Indian pharma exporters.
- −Promoter pledge activity was recorded in May 2026 — a SEBI SAST disclosure of 2,86,213 shares pledged and released by promoter Aayush Agrawal — a governance transparency item that warrants tracking across subsequent quarters.
- −Analyst coverage is limited to 14 analysts with a mean rating of 1.31 on a 1-5 scale (lower = more constructive); the small coverage base means a single revision or downgrade has an outsized impact on the consensus read.
Open questions
- ?Given the rising D/E of 5.747 alongside high-teen revenue growth guidance, is the incremental debt being deployed into capacity that will be reflected in margins within 2-3 years, or is it servicing existing obligations at rates that compress future FCF?
- ?How have prior US FDA Form 483 observations at Ajanta Pharma facilities been resolved historically — were they closed within one inspection cycle, or did any escalate to Warning Letters affecting shipment volumes?
- ?Does the ROE of 25.4% reflect a structural pricing advantage in niche therapeutic segments (ophthalmology, dermatology) or is it driven by a period of favorable product mix that could normalize as competition increases?
- ?With 4 of 5 sector peers lacking ROE and 1-year price-change data in this dataset, how does Ajanta Pharma compare to a broader pharma mid-cap universe on leverage-adjusted return metrics over a five-year horizon?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| AJANTPHARM | Ajanta Pharmaceuticals Ltd.You're viewing | 37.6 | +25.4% | 65 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹3,177.20
SMA 50
₹2,907.57
SMA 200
₹2,697.79
RSI (14)
66.6 (neutral)
From 52w high
-3.4%
1Y return
+29.4%
3M return
+9.3%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumDebt-to-equity of 5.747 with a rising trend is elevated for a mid-cap pharma company. FCF has been positive in 4 of 5 available years, but the combination of high leverage and an upward debt trajectory warrants scrutiny of capex intent and interest-coverage capacity.
- mediumUS FDA issued Form 483 with five observations at the Paithan manufacturing plant in April 2026. Unresolved observations can escalate to a Warning Letter, which would restrict US-market sales and affect a significant export revenue channel.
- lowTotal news items captured is 6, which is sparse. The sentiment split is exactly 2 positive / 2 neutral / 2 negative, leaving the overall neutral label fragile — a single additional item in either direction shifts the read materially.
- lowROE and 1-year price-change data are unavailable for 4 of 5 peer comparators; quality-score and PE rankings are partially validated only, and peer ROE comparison is limited to Cipla (11.74%) and Dr. Reddys (11.84%).
Cross-section contradictions
- D/E of 5.747 on a rising trend coexists with ROE of 25.4% and positive FCF in 4 of 5 years — unusually high leverage paired with sustained profitability may reflect deliberate capacity-expansion financing, but the debt trajectory diverges from the earnings quality signal and merits independent verification.
- Overall news sentiment is neutral (2 positive, 2 neutral, 2 negative) while the stock is up 29.4% over 12 months and trades just 3.4% below its 52-week high — the constructive price action has not been accompanied by equally constructive news flow, and the FDA Form 483 is an unpriced latent risk.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days